NSCLC

[Future Oncology] The authors take stock of the relationship between epidermal growth factor receptor (EGFR) mutations and PD-1 and its ligand receptor 1expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.

[Bristol Myers Squibb] Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Opdivo plus chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.

[Merck KGaA] Merck KGaA, announced that the European Commission has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.

[Signal Transduction and Targeted Therapy] Scientists indicated that targeting IL6/JAK2/STAT3 signaling in activated microglia might be a promising new approach for inhibiting brain metastasis in NSCLC patients.

[Communications Biology] Researchers used a humanized mouse model to show that while carboplatin plus pembrolizumab reduced tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2, delivered systemically in nanovesicles, to this combination, eradicates tumors in the majority of animals.

[Communications Biology] The authors showed that clinically, plasma interleukin-6 (IL-6) level predicted osimertinib efficacy in epidermal growth factor receptor mutant NSCLC patients.